San Francisco Department of Public Health Confirms First Clade I Mpox Case in San Francisco
https://www.sf.gov/news-san-francisco-department-of-public-health-confirms-first-clade-i-mpox-case-in-san-francisco
Brief quote: “On April 14, the San Francisco Department of Public Health (SFDPH) confirmed the first case of clade I mpox in a San Francisco resident. The case occurred in an unvaccinated adult who was hospitalized and is improving. The individual reported close contact with someone who traveled internationally.
SFDPH strongly encourages people at risk for mpox to receive both doses of the mpox vaccine. The vaccine provides the best protection against the mpox virus and protects against both clade I and clade II. At this time, mpox exposure risk is low for individuals who are not in higher‑risk groups.
The mpox vaccine is available through healthcare providers and local pharmacies. Those who do not have insurance or are having difficulty accessing care may visit the locations listed at sf.gov/mpox.”
The JYNNEOS vaccine (also known as Imvamune or Imvanex) is the primary vaccine used to prevent mpox, approved for adults 18+ at high risk of exposure. It is a two-dose series (given 4 weeks apart) administered subcutaneously or intradermally. Monkeypox vaccines are expected to be protective against monkeypox regardless of clade or subclade and the vaccine can be given as post exposure prophylaxis.
Brief quote: “On April 14, the San Francisco Department of Public Health (SFDPH) confirmed the first case of clade I mpox in a San Francisco resident. The case occurred in an unvaccinated adult who was hospitalized and is improving. The individual reported close contact with someone who traveled internationally.
SFDPH strongly encourages people at risk for mpox to receive both doses of the mpox vaccine. The vaccine provides the best protection against the mpox virus and protects against both clade I and clade II. At this time, mpox exposure risk is low for individuals who are not in higher‑risk groups.
The mpox vaccine is available through healthcare providers and local pharmacies. Those who do not have insurance or are having difficulty accessing care may visit the locations listed at sf.gov/mpox.”
The JYNNEOS vaccine (also known as Imvamune or Imvanex) is the primary vaccine used to prevent mpox, approved for adults 18+ at high risk of exposure. It is a two-dose series (given 4 weeks apart) administered subcutaneously or intradermally. Monkeypox vaccines are expected to be protective against monkeypox regardless of clade or subclade and the vaccine can be given as post exposure prophylaxis.
